deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT01937468

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

A Phase I Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Sponsor: Dana-Farber Cancer Institute

Conditions Chronic GVHD Chronic Graft Versus Host Disease Complications of Organ Transplant Stem Cells
Interventions Interleukin-2 Treg-enriched infusion
Updated 22 times since 2017 Last updated: Feb 3, 2026 Started: Nov 30, 2013 Primary completion: Aug 31, 2017 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01937468, this PHASE1 trial focuses on Chronic GVHD and Chronic Graft Versus Host Disease and remains ongoing. Sponsored by Dana-Farber Cancer Institute, it has been updated 22 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Mar 2019 · 8 months · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Feb 2020 · 7 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Feb 2024 · 10 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~Oct 2025 · 7 months · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

22 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Dec 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 17 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  3. Apr 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  6. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1

  8. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  9. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  10. Feb 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

  11. Jul 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  12. Mar 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE1

  13. Jul 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE1

  14. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE1

  15. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  16. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  17. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Iovance Biotherapeutics, Inc.
  • Miltenyi Biomedicine GmbH
  • National Cancer Institute (NCI)
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations